Product Reports Resources Pricing Login Book a demo

EQRx

Biotech & Life Sciences · Cambridge, United States · Founded 2019 · Public via SPAC 2021

Biotech company aimed at creating less expensive medicine MoreLess

EQRx is a biotechnology company focused on developing and delivering innovative medicines at significantly lower prices. The company aims to address the high cost burden of healthcare by creating a catalog of new medicines that are more affordable and accessible. EQRx operates in the pharmaceutical and healthcare markets, targeting disease areas with the highest cost burdens on society. The business model revolves around leveraging cutting-edge innovation and strategic collaborations to produce high-quality, cost-effective treatments. EQRx generates revenue by bringing these affordable medicines to market, thereby increasing access to essential healthcare solutions for a broader population. The company's clients include healthcare providers, patients, and payers who benefit from reduced costs and improved access to new treatments. EQRx's mission is to transform the healthcare system by making it more sustainable and equitable through innovative and affordable medical solutions.

Keywords: biotechnology, affordable medicines, healthcare innovation, pharmaceutical, cost-effective treatments, strategic collaborations, disease burden, healthcare providers, patients, payers.

Headcount <100
Total funding $1–2.5B

Talent graph

EQRx's talent

Book a demo to see the people
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

21 investors on EQRx's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 8 investors entered at this stage
Series B+ 13 investors entered at this stage
Verily
Boxer Capital
Mubadala Capital
Bain Capital Life Sciences
Corvex Management
Fidelity Investments
SoftBank
Invus
Rock Springs Capital
Franklin Templeton Investments
BVF Partners
Avidity Partners
CM Life Sciences III

Global footprint

Where EQRx has talent and traffic

Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown
Web traffic by country
560 monthly visits
across markets
🇺🇸 United States107.1%
Top 1 markets shown

Market sentiment

What the market is saying about EQRx

An AI-synthesized read of the highest-engagement posts about EQRx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See EQRx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.